Inspiration-phased oxygen delivery

Supportive therapy in COPD

Supportive therapy in COPD includes long-term oxygen therapy (LTOT) and patient support groups as two cornerstones in a comprehensive program of care known as pulmonary rehabilitation. The rich history of LTOT dating to the early 1960s and bolstered by excellent controlled clinical trials of the 1970s, along with additional advances, provided an effective therapy which improved both the quality and length of life in patients with COPD. Many patients with oxygen gain insight into coping with advanced COPD through patient support groups. The need for more cosmetically pleasing oxygen delivery systems to the nose, and future directions in providing oxygen in the home, remain challenges.

Oxygen therapy using pulse and continuous flow with a transtracheal catheter and a nasal cannula

Pulse delivery (PD) of oxygen was compared with continuous flow (CF) utilizing transtracheal oxygen catheter (TTO) and nasal cannula (NC) in 20 stable patients with chronic hypoxemia. Oxygen saturation, respiratory rate, and accuracy of pulsed oxygen delivery were measured during sleep studies and these parameters, as well as arterial blood gases, were evaluated during rest and exercise. Additionally, bulk liquid oxygen use was measured under each condition, for a period of 1 month. Pulse delivery NC was evaluated in six subjects, CF NC in 14 subjects, and PD and CF TTO in 20 subjects over the 1-month period. Results showed that, as a group, patients were adequately oxygenated when utilizing the PD with both NC and TTO as assessed by arterial blood gases, oximetry, and hematocrit. However, four subjects could not be adequately oxygenated on PD NC during exercise even at the maximum liter per minute setting and could not be studied with this mode of therapy. The PD settings in the remaining subjects were equivalent to continuous flow settings for TTO and NC as assessed by PaO2 for rest and SaO2 for exercise and sleep. Compared with standard CF NC, the daily bulk oxygen use was decreased by 29.4 percent with CF TTO, by 48.2 percent with PD NC, and by 49.9 percent with PD TTO. We conclude that, compared with CF NC, PD of oxygen via TTO or NC by this method appears to be a safe, reliable, effective, and cost-effective method of oxygen delivery in the majority of subjects when used with proper screening.

Efficacy of a pulsed oxygen delivery device during exercise in patients with chronic respiratory disease

The ability of a pulsed oxygen delivery system (Puritan-Bennett Companion Oxygen Saver (COS-5) to track respiratory rate during exercise and the oxygenation achieved during the exercise while oxygen was being delivered by this system was compared to that attained while oxygen was delivered continuously in six patients with chronic obstructive pulmonary disease (COPD) and six patients with idiopathic pulmonary fibrosis (IPF). The COS-5 appeared to respond appropriately at respiratory rates between 15 and 45, even when there were minimal pressure changes at the nose. There was an excellent correlation in PaO2 at equivalent flow settings during the exercise in the patients with COPD and IPF. There were six instances (in four patients) of the 31 comparisons in which the PaO2 differed by more than 5 mm Hg. The PaO2 was higher with continuous oxygen delivery on two occasions in a patient with COPD who utilized pursed-lip breathing during the exercise. The PaO2 was higher with COS-5 delivery on two occasions in a patient with IPF who was breathing at the highest respiratory rates (44 and 45/min) during the exercise.

Clinical assessment of oxygen conserving devices in chronic bronchitis and emphysema

We have studied the efficacy of three devices designed to conserve oxygen delivered to patients with hypoxic chronic bronchitis and emphysema. Devices A and B are valve systems, which deliver oxygen only during inspiration. Device C is a modified nasal prongs system incorporating a "moustache reservoir" (Oxymizer, Chad Therapeutics Inc, Woodland Hills, California), which is claimed to produce a higher arterial oxygen saturation (SaO2) from a given flow of oxygen than does continuous delivery through nasal prongs. Devices A and B were found to give the same oxygen saturation as continuous flow oxygen, but only device B reduced the flow of oxygen significantly (p less than 0.01). The flow characteristics of device A were likely to be the cause of this failure to conserve oxygen. Device C produced a higher mean rise in SaO2 than did standard nasal prongs at all oxygen flow rates, and was able to achieve the same rise in SaO2 as standard nasal prongs with a small (25-33%) saving in oxygen delivery. There was, however, considerable variation between patients in the oxygen saving efficiency of device C, with little or no oxygen saving in seven of the 12 patients studied.